Compare Organon & Co. Common Stock (OGN) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Toronto-Dominion Bank — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Toronto-Dominion Bank trades at $117.63 (market cap $191.91B). The key difference: Toronto-Dominion Bank is far larger — about 53× Organon & Co. Common Stock's market cap, and Toronto-Dominion Bank pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Toronto-Dominion Bank for 85 Days on average.
| OGN | TD | |
|---|---|---|
Market Cap | $3.62B | $191.91B |
Volume | 2,892,999 | 1,115,140 |
Sector | Health | Financials |
52-Week High | $13.81 | $124.80 |
52-Week Low | $5.70 | $78.72 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $11.04B | $568.32B |
Dividend Yield | 0.58% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TD (Toronto-Dominion Bank) trades at $117.63, up 0.98% today, with a bearish technical signal but strong fundamentals including a P/E of 18.01 and net income margin of 24.88%. Recent earnings have consistently beaten estimates, and the company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30). Cash flow trends show volatility, with 2025 net cash flow at $1.08 billion. The stock faces headwinds from a high debt-to-asset ratio of 20.86 in 2025, though analyst consensus is bullish with 52.94% buy ratings.
The outlook for TD is mixed: solid profitability and shareholder returns via buybacks and dividends support upside, but technical weakness and elevated debt pose risks. Investors should weigh strong earnings momentum against macroeconomic sensitivity and regulatory scrutiny from ongoing anti-money laundering remediation. The stock's valuation appears reasonable relative to peers, but market sentiment remains cautious due to cash flow inconsistencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
